Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus

ConclusionsOur data suggest that de novo use of EVL may reduce late onset CMV primary disease after the withdrawal of antiviral prophylaxis in kidney transplantation patients.

Source: Transplant Infectious Disease - February 21, 2018 Category: Transplant Surgery Authors: Arnaud Devresse, Marianne Leruez ‐Ville, Anne Scemla, Véronique Avettand‐Fenoel, Lise Morin, Xavier Lebreton, Claire Tinel, Lucile Amrouche, Lionel Lamhaut, Marc Olivier Timsit, Julien Zuber, Christophe Legendre, Dany Anglicheau Tags: ORIGINAL ARTICLE Source Type: research